Lei Chen is a skilled biotechnologist currently serving as the CTO and co-founder of Rarity Bioscience. They earned a PhD in Molecular Medicine from Uppsala University, where they developed the SafeLock assay under the guidance of Prof. Ulf Landegren. Lei also completed a postdoctoral research project, advancing the superRCA assay for Acute Myeloid Leukemia mutation detection. Additionally, they hold a Master's degree in Applied Biotechnology and a Bachelor's degree in Biotechnology from Nanjing University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices